Computational screening of molecular targets in Plasmodium for novel non resistant anti-malarial drugs
نویسندگان
چکیده
Histone acetyltransferase (HAT) is an enzyme required for chromatin remodeling and transcriptional activation. Sarcoendoplasmic reticulum Ca(2+) ATPase (SERCA) is an ATP coupled Ca(2+) ion pump involved in metabolic arrest. Both these enzymes are present in Plasmodia and have been selected as molecular targets for in silico studies of some new non-resistant antimalarial drugs like artemisinin, curcumin and diarylheptanoids along with some other inhibitors reported in literature. Ten top inhibitors have also been generated based on common pharmacophore from ZINC database. The HAT enzyme was modeled with the help of the Modeller software and the SERCA enzyme pdb file was obtained from the protein data bank. Ligbuilder was used for structure based drug designing, which generated a common pharmacophore of the ligands. Molegro was used to perform virtual screening of the hits from the pharmacophore based Zinc database search and known inhibitors of the enzymes from the literature survey. Curcumin shows good and optimal binding to both HAT and SERCA enzymes; therefore it might be a good inhibitor of these key enzymes in Plasmodium. Curcumin is reported to act synergistically with artemisinin which forms covalent adducts with the transmembrane proteins (SERCA enzyme) and inactivates them, thus inhibiting the activity of Plasmodium parasite. This combination has already been reported to be effective in malaria treatment. Some other diarylheptanoids besides curcumin showed better binding to both the enzymes. Therefore, a combination of artemisinin and diarylheptanoids can prove to be better combination for antimalarial therapy. Different formulations involving curcumin, artimisinin and diarylheptanoids may result in a more potent antimalarial drug.
منابع مشابه
Conservation of gene essentiality in Apicomplexa and its
New anti-malarial drugs are needed to address the challenge of artemisinin resistance and to achieve malaria elimination and eradication. Target-based screening of inhibitors is a major approach for drug discovery, but its application to malaria has been limited by the availability of few validated drug targets in . Here we utilize the recently available large-scale gene Plasmodium essentiality...
متن کاملComparative modeling of Plasmodium falciparam Dihydropteroate Synthase 2 and docking study against compounds from anti-malarial plant Carcia papaya and Swertia chirata
Malaria parasite Plasmodium falciarum are becoming drug resistant and the present drugs are becoming ineffective towards the disease. The Plasmodium falciparum causes the most malignant form of malaria highly prevalent to North–East India. In this investigation, a study was conducted to search and predict potent anti-malarial lead compounds from two traditionally important anti-malarial plant, ...
متن کاملStructural model of the Plasmodium falciparum thioredoxin reductase:a novel target for antimalarial drugs.
BACKGROUND Malaria, a scourge of mankind, imposes a huge socioeconomic burden in tropical countries. Emergence of multi-drug resistant malarial parasites impels us to explore novel drug targets. Thioredoxin reductase is a promising antimalarial drug target. METHODS The Thioredoxin reductase enzyme of Plasmodium falciparum was characterized in silico and protein disorder was predicted using av...
متن کاملCurrent opinion on an emergence of drug resistant strains of Plasmodium falciparum through genetic alterations
The human malarial parasite Plasmodium falciparum is one of the world's most devastating pathogen. Its capability to regulate its genes under various stages of its life cycle as well as under unfavourable environmental conditions has led to the development of vaccine resistant strains. Similarly, under drug pressure it develops mutations in the target genes. These mutations confer mid and high-...
متن کاملProfiling of the anti-malarial drug candidate SC83288 against artemisinins in Plasmodium falciparum
BACKGROUND The increased resistance of the human malaria parasite Plasmodium falciparum to currently employed drugs creates an urgent call for novel anti-malarial drugs. Particularly, efforts should be devoted to developing fast-acting anti-malarial compounds in case clinical resistance increases to the first-line artemisinin-based combination therapy. SC83288, an amicarbalide derivative, is a ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Bioinformation
دوره 3 شماره
صفحات -
تاریخ انتشار 2009